1.Latent class analysis of therapeutic effects of Huoxiang Zhengqi Oral Liquid on patients with cold due to wind-cold and dampness stagnation.
Miao WU ; Shi-Sui LUO ; Jin YIN ; Si-Cen JIN ; Lin SUN ; Hao-Qi ZHOU ; Xin-Ting HUANG ; Xiao-Hua ZHOU
China Journal of Chinese Materia Medica 2024;49(21):5944-5950
The demographic characteristics, drug use, clinical symptoms and other data of the patients treated with Huoxiang Zhengqi Oral Liquid were collected. The latent class analysis(LCA) was performed to reveal the distribution of primary symptoms, and then the doubly robust estimation was employed to analyze the efficacy of different doses of Huoxiang Zhengqi Oral Liquid in different populations. A total of 11 273 patients were enrolled in this study, including 4 347 males and 6 926 females. A total of 15 primary symptoms were included, with the top 3 being dizziness(53.9%), head heaviness(39.6%), and nausea(39.4%). According to the LCA, the population was divided into 3 groups of spleen deficiency and dampness exuberance(5 604 cases, 49.71%), upward harassing of wind-phlegm(4 955 cases, 43.96%), and spleen Qi deficiency(714 cases, 6.33%). Double robust estimation showed that the time to recovery of the patients with spleen Qi deficiency had no significant difference regarding the daily dose. Compared with the daily dose of 20 mL, the daily doses of 40, and 60 mL shortened the time to recovery by 16.67(95%CI[5.23, 28.12]) and 15.94 h(95%C1[7.45, 24.43]) in the patients with upward harassingof wind-phlegm, the daily doses of 30, 40, and 60 mL shortened the time to recovery by 4.42(95%CI[1.06, 7.77]), 13.07(95%CI[1.61, 24.54]), 13.92 h(95%CI[5.14, 22.70]) in the patients with spleen deficiency and dampness exuberance, respectively. The patients with cold due to wind-cold and dampness stagnation had more primary syndromes, and the disease locations were mainly in the head, stomach, and spleen. In clinical practice, the daily dose of Huoxiang Zhengqi Oral Liquid can be increased according to the symptoms of patients, which can shorten the time to recovery.
Humans
;
Male
;
Female
;
Drugs, Chinese Herbal/therapeutic use*
;
Middle Aged
;
Adult
;
Young Adult
;
Aged
;
Adolescent
;
Administration, Oral
;
Wind
;
Child
;
Spleen/drug effects*
;
Cold Temperature
;
Aged, 80 and over
2.Progress on clinical features, pathological mechanisms, assessment and prognosis of hearing loss in systemic lupus erythematosus.
Zi He ZHAO ; Ao LI ; Shao Qin CEN ; Guang Jie ZHU ; Han ZHOU ; Si Yu LI ; Yin CHEN ; Xiao Yun QIAN ; Xia GAO
Chinese Journal of Otorhinolaryngology Head and Neck Surgery 2023;58(2):165-170
3.Research advances in the study of anticoagulant active molecules
Kang-jia SHENG ; Yan GAO ; Tao BAO ; Si-cen WANG
Acta Pharmaceutica Sinica 2023;58(5):1103-1116
The incidence of thrombosis-induced cardiovascular diseases is increasing worldwide and poses a serious threat to human health. Three factors, slow speed of blood flow, hypercoagulable blood and vascular damage, have been considered to be causes of thrombosis. Antithrombotic drugs have been classified into three categories based on the mechanism of thrombosis, including anticoagulants, platelet inhibitors and fibrinolytics. The coagulation and anticoagulation systems have drawn increasing attention because of the important role they play in the process of thrombosis. Novel compounds with anticoagulant activity are now emerging, alleviating to some extent some of the problems associated with the clinical use of early approved thrombotic drugs, such as high bleeding risk, slow onset of action and narrow therapeutic windows. In this review, we initially describe the mechanisms of coagulation as well as thrombosis. Meanwhile, a wide range of bioactive compounds and potential antithrombotic candidates reported in recent years have been summarized. In addition, the structure-activity relationship of certain compounds has been discussed, expecting to facilitate the development of molecules with anticoagulant biological activity for the treatment of thrombotic diseases.
4.Mechanism of heat-clearing prescriptions in alleviating type 2 diabetes mellitus:a review.
Yan WANG ; Jian-Qing LIANG ; Xiang-Dong ZHU ; Peng-Peng GAO ; Xi CEN ; Yong-Lin LIANG ; Jie LI ; Ying-Yun WANG ; Xiao-Li SI
China Journal of Chinese Materia Medica 2023;48(7):1711-1723
Type 2 diabetes mellitus(T2DM), a common chronic metabolic disease, is often accompanied by internal heat syndrome. Heat-clearing prescriptions are widely used to treat different heat syndromes of T2DM from the aspects of clearing stagnant heat, excess heat, damp heat, phlegm heat, and heat toxin, demonstrating remarkable effects. The mechanism of blood sugar-lowering agents has always been a hotspot of research. Recently, the basic studies of heat-clearing prescriptions from different perspectives have been increasing year by year. To clarify the mechanisms of heat-clearing prescriptions and find specific mechanisms, we systematically reviewed the basic studies of heat-clearing prescriptions commonly used for the treatment of T2DM in the past decade, intending to provide a reference for related research.
Humans
;
Diabetes Mellitus, Type 2/drug therapy*
;
Drugs, Chinese Herbal/therapeutic use*
;
Hot Temperature
;
Medicine, Chinese Traditional
;
Prescriptions
;
Syndrome
5.The Mechanism of miR-1294 Targeting SOX15 to Regulate Wnt/β-catenin Signaling Pathway and Promote the Proliferation of Acute Lymphoblastic Leukemia Cells in Children.
Hong-Xia CEN ; Si-Ming CAI ; Hong-Yu JIANG ; Zhao-Mei LIAO ; Dong-Guang HAN
Journal of Experimental Hematology 2023;31(2):344-351
OBJECTIVE:
To explore the effect of abnormal miRNA expression on the proliferation of pediatric acute lymphoblastic leukemia (ALL) cells and its related mechanism.
METHODS:
15 children with ALL and 15 healthy subjects were collected from the Second Affiliated Hospital of Hainan Medical University from July 2018 to March 2021. MiRNA sequencing was performed on their bone marrow cells, and validated using qRT-PCR. MiR-1294 and miR-1294-inhibitory molecule (miR-1294-inhibitor) were transfected into Nalm-6 cells, and the proliferation of Nalm-6 cells was detected by CCK-8 and colony formation assays. Western blot and ELISA were used to detect apoptosis of Nalm-6 cells. Biological prediction of miR-1294 was performed to find the target gene, which was verified by luciferase reporter assay. Si-SOX15 was transfected into Nalm-6 cells, Western blot was used to detect the expression of Wnt signaling pathway-related proteins and to verify the effect of si-SOX15 on the proliferation and apoptosis of Nalm-6 cells.
RESULTS:
Compared with healthy subjects, 22 miRNAs were significantly upregulated in bone marrow cells of ALL patients, of which miR-1294 was the most significantly upregulated. In addition, the expression level of SOX15 gene was significantly reduced in bone marrow cells of ALL patients. Compared with the NC group, the miR-1294 group showed increased protein expression levels of Wnt3a and β-catenin, faster cell proliferation, and more colony-forming units, while caspase-3 protein expression level and cell apoptosis were reduced. Compared with the NC group, the miR-1294-inhibitor group showed reduced protein expression levels of Wnt3a and β-catenin, slower cell proliferation, and fewer colony-forming units, while caspase-3 protein expression level was increased and apoptosis rate was elevated. miR-1294 had a complementary base-pair with the 3'UTR region of SOX15 , and miR-1294 directly targeted SOX15 . The expression of miR-1294 was negatively correlated with SOX15 in ALL cells. Compared with the si-NC group, the si-SOX15 group showed increased protein expression levels of Wnt3a and β-catenin, accelerated cell proliferation, and decreased caspase-3 protein expression level and cell apoptosis rate.
CONCLUSION
MiR-1294 can target and inhibit SOX15 expression, thus activating the Wnt/β-Catenin signaling pathway to promote the proliferation of ALL cells, inhibit cell apoptosis, and ultimately affect the disease progression.
Humans
;
Child
;
beta Catenin/genetics*
;
Wnt Signaling Pathway
;
Caspase 3/metabolism*
;
Cell Line, Tumor
;
MicroRNAs/genetics*
;
Cell Proliferation
;
Precursor Cell Lymphoblastic Leukemia-Lymphoma
;
Apoptosis
;
SOX Transcription Factors/metabolism*
6.Establishment of a cocrystal characterization method for sacubitril valsartan sodium
Jing XIONG ; De-zhong XU ; Xin-yi XU ; Yang LÜ ; Shi-ying YANG ; Si-cen WANG
Acta Pharmaceutica Sinica 2021;56(2):577-584
Sacubitril valsartan sodium (LCZ696) is an ionic cocrystal drug. The purpose of this study was to explore the cocrystal features of LC696 by establishing a variety of characterization methods, and thus provide basic research data for effective quality control. The cocrystal characteristics of LCZ696 and its tablets were identified by applying analytical means including powder X-ray diffraction (PXRD), fourier transform infrared spectroscopy (FTIR), Raman spectra (RM), differential scanning calorimetry (DSC) and solid-state nuclear magnetic resonance spectroscopy (ssNMR). The crystalline water and hygroscopicity of LCZ696 were analyzed by thermogravimetric analysis (TGA), dynamic vapor sorption (DVS), hygroscopicity test and Karl Fischer reaction method. The results show that PXRD, FTIR, DSC and ssNMR can effectively distinguish the features of LCZ696 cocrystal, sacubitril monomer, valsartan monomer, and sacubitril-valsartan (1∶1) mixture. RM can be used as a supplementary approach. Combined with the analysis by TGA, DVS, hygroscopicity test and Karl Fischer reaction method results, LCZ696 contains 2.5 crystalline water molecules and is very hygroscopic; we recommend that LCZ696 be stored in an environment with a relative humidity below 60%. By characterizing the crystal features we can establish quality control measure and evaluate the stability of the drug tablets. This study provides data in support for the establishment of the LCZ696 quality standard.
7.Paeoniflorin regulates gut microbiota and bile acids metabolism in colitis mice
Xin WANG ; Min ZHU ; Si-jing DONG ; Yin-yue XU ; Wang-hui JING ; Si-cen WANG
Acta Pharmaceutica Sinica 2021;56(7):1811-1819
The current study was designed to evaluate the modulatory effects of paeoniflorin on the dysregulated gut microbiota as well as the disturbed fecal bile acids (BAs) in colitis mice. After approved by Xi'an Jiaotong University Ethics Committees (Approval No. XJTU2019-679), the animals were randomly distributed into the control (Con), colitis, low dose paeoniflorin (PF-L, 25 mg·kg-1·d-1), high dose paeoniflorin (PF-H, 50 mg·kg-1·d-1) and 5-aminosalicylic acid (5-ASA, 50 mg·kg-1·d-1) groups. Colitis was induced by administering 3% (
8.Advance in Role of Mitochondrial Quality Control in Exercise for Sarcopenia (review)
Cen-yi WANG ; Ji-ling LIANG ; Yu-hao SI ; Ning CHEN
Chinese Journal of Rehabilitation Theory and Practice 2020;26(9):1066-1070
Sarcopenia is a process in which skeletal muscle mass and strength are gradually declining, resulting a main health challenge for the old adults. Mitochondria can maintain the integrity of structure and function of skeletal muscle by improving biosynthesis, antioxidant defense, fusion/fission dynamics and mitophagy. Mitochondrial dysfunction is a important factor leading to the complex etiology of sarcopenia. Exercise can regulate mitochondrial quality control pathways by activating mitochondrial biogenesis and mitophagy to maintain optimal mitochondrial function, thereby delaying and preventing the onset and progression of sarcopenia.
9.Genetic profile of Chinese patients with Charcot-Marie-Tooth disease.
Zhi-Yuan OUYANG ; You CHEN ; Da-Qiang QIN ; Zhi-Dong CEN ; Xiao-Sheng ZHENG ; Fei XIE ; Si CHEN ; Hao-Tian WANG ; De-Hao YANG ; Xin-Hui CHEN ; Le-Bo WANG ; Bao-Rong ZHANG ; Wei LUO
Chinese Medical Journal 2020;133(21):2633-2634
10.Clinical feature changes of a COVID-19 patient from mild to critical condition and cardiopulmonary pathological results.
Si Wei JIANG ; Hong GAO ; Lin WU ; Guo Wei WANG ; Fu Lan CEN ; Jin Xiu LI ; Cheng FENG ; Jun Min WEN ; Ye CHEN ; Ren Liang HE ; Kun QIAO ; Ying WANG ; Ying Xia LIU ; Zhao Qin WANG
Chinese Journal of Cardiology 2020;48(7):580-586
Objective: To analyse the clinical history, laboratory tests and pathological data of a patient who suffered from novel coronavirus pneumonia(COVID-19) and provide reference for the clinical treatment of similar cases. Methods: Data of clinical manifestation, laboratory examination, bronchoscopy, echocardiography and cardiopulmonary pathological results were retrospectively reviewed in a case of COVID-19 with rapid exacerbation from mild to critical condition. Results: This patient hospitalized at day 9 post 2019 novel coronavirus(2019-nCoV) infection, experienced progressive deterioration from mild to severe at day 12, severe to critical at day 18 and underwent extracorporeal membrane oxygenation(ECMO) and continuous renal replacement therapy(CRRT) as well as heart lung transplantation during day 28-45 post infection, and died at the second day post heart and lung transplantation. The patient had suffered from hypertension for 8 years. At the early stage of the disease, his symptoms were mild and the inflammatory indices increased and the lymphocyte count decreased continuously. The patient's condition exacerbated rapidly with multi-organ infections, and eventually developed pulmonary hemorrhage and consolidation, pulmonary hypertension, right heart failure, malignant ventricular arrhythmias, liver dysfunction, etc. His clinical manifestations could not be improved despite viral RNAs test results became negative. The patient underwent lung and heart transplantation and finally died of multi organ failure at the second day post lung and heart transplantation. Pathological examination indicated massive mucus, dark red secretions and blood clots in bronchus. The pathological changes were mainly diffused pulmonary hemorrhagic injuries and necrosis, fibrosis, small vessel disease with cardiac edema and lymphocyte infiltration. Conclusions: The clinical course of severe COVID-19 can exacerbate rapidly from mild to critical with lung, liver and heart injuries.
Betacoronavirus
;
COVID-19
;
Coronavirus Infections/pathology*
;
Fatal Outcome
;
Hemorrhage/virology*
;
Humans
;
Lung/pathology*
;
Myocardium/pathology*
;
Pandemics
;
Pneumonia, Viral/pathology*
;
Retrospective Studies
;
SARS-CoV-2

Result Analysis
Print
Save
E-mail